Youngevity Urges FDA to Require Selenium in Infant Formula
The Proposed Rule would require inclusion of selenium in infant formula, which has now been confirmed by the FDA to be "an essential trace element for humans" adding that selenium deficiencies "may be of greatest concern in infants and children" especially to those that are entirely fed through formula.
In support of the Proposed Rule, Youngevity and its distributors filed official Comments reiterating selenium's integral role as part of a healthy diet. Youngevity's Comment also relied on an evaluation by noted researcher, chemist, and scholar Dr. G.N. Schrauzer, Ph.D. who also serves on Youngevity's Scientific Advisory Board. Citing Dr. Schrauzer's expert opinion, Youngevity recommended that the FDA require the use of an organic form of selenium, selenomethionine, which provides greater health benefits to humans than does the mineral's inorganic form, sodium selenate.
Youngevity has long been a strong advocate of providing the public with important, truthful information about such health benefits and this is only the latest measure taken in support of health derived from supplementation. Youngevity has already successfully petitioned the FDA to allow such claims concerning the consumption of certain omega-3 fatty acids to reduce the risk of coronary heart disease and of the consumption of selenium to reduce the risk of bladder cancer in women as well as prostate and thyroid cancers.
Youngevity CEO, Steve Wallach, stated, "My father, and Youngevity founder, Dr. Joel Wallach, has been at the forefront of Selenium research for nearly 40 years and the Proposed Rule would only amplify the importance of mineral supplementation, especially to children who rely on infant formula as their only nutrient source."
The FDA will continue to accept comments on its Proposed Rule until July 1, 2013.
More Youngevity news
SEC Revokes Youngevity Stock Registration Over Three Years of Missing Reports
The Securities and Exchange Commission on December 5, 2023 issued an order revoking the registration of each class of Youngevity International, Inc. securities under Section 12(j)...
Youngevity Completes Restatement of Its 2019 Quarterly Statements
Youngevity International said it completed the restatement of quarterly financial statements for the year ended December 31, 2019. Chairman and chief executive Steve Wallach said...
Youngevity Aims to Regain a Nasdaq Listing by July 2021
Youngevity International told shareholders why its YGYI securities left the Nasdaq Stock Market on November 19, 2020, and how it hopes to be listed again. The company said the...
Nasdaq Panel Moves to Delist Youngevity After Late Filings
Youngevity International said a Nasdaq Hearings Panel notified the company that its securities will be delisted from the Nasdaq Stock Market. The panel acted because the company...
Youngevity Appoints MaloneBailey as Auditor and William Thompson as CFO
Youngevity International, Inc. appointed MaloneBailey, LLP as its independent registered public accounting firm to audit its financial statements. It also named William G....